The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical Results
Abstract
Purpose: We studied the safety, clinical activity, and pharmacokinetics (PK) of AG-013736, an oral receptor tyrosine kinase inhibitor of vascular endothelial cell growth factor, platelet-derived growth factor, and c-Kit, in patients with advanced cancer. Patients and Methods: Patients received fixed doses of AG-013736 orally in 28-day cycles. In the first cohort, patients initially received two single test doses of AG-013736 (10 and 30 mg); subsequent dosing was determined by individual PK parameters. Doses in subsequent cohorts were assigned by using a traditional dose-escalation/de-escalation rule based on observed toxicities in the current and previous cohorts. PK analysis included evaluation of the effect of food and antacid. Results: Thirty-six patients received AG-013736 at doses ranging from 5 to 30 mg by mouth twice daily. The dose-limiting toxicities observed included hypertension, hemoptysis, and stomatitis and were seen primarily at the higher dose levels. The observed hypertension was manageable with medication. Stomatitis was generally tolerable and managed by dose reduction or drug holidays. AG-013736 was absorbed rapidly, with peak plasma concentrations observed within 2 to 6 hours after dosing. The maximum-tolerated dose and recommended phase II dose of AG-013736 is 5 mg, twice daily, administered in the fasted state. No significant drug interaction with antacid was seen. There were three confirmed partial responses and other evidence of clinical activity. Conclusion: In this study, we have demonstrated clinical activity and safety of AG-013736 in patients with advanced solid tumors and identified the dose for phase II testing. The unique phase I study design allowed early identification of important absorption and metabolic issues critical to phase II testing of this agent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,687
Role of angiogenesis in tumor growth and metastasis
Folkman, J. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.37263 · Cited by 2,404
Role of angiogenesis in tumor growth and metastasis
FOLKMAN, J. (2002) · Seminars in Oncology · doi:10.1016/s0093-7754(02)70065-1 · Cited by 2,400
Willett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., et al. (2004) · Nature Medicine · doi:10.1038/nm988 · Cited by 1,966
Induction of angiogenesis during the transition from hyperplasia to neoplasia
Folkman, J., Watson, K., Ingber, D., & Hanahan, D. (1989) · Nature · doi:10.1038/339058a0 · Cited by 1,879
Clinical translation of angiogenesis inhibitors
Kerbel, R., & Folkman, J. (2002) · Nature Reviews Cancer · doi:10.1038/nrc905 · Cited by 1,517
Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E., & Hanahan, D. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17929 · Cited by 1,370
Cited by
Lessons from phase III clinical trials on anti-VEGF therapy for cancer
Jain, R. K., Duda, D. G., Clark, J. W., & Loeffler, J. S. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0403 · Cited by 1,039
Cohen, E. E. W., Rosen, L. S., Vokes, E. E., Kies, M. S., Forastiere, A. A., Worden, F. P., Kane, M. A., Sherman, E., Kim, S., Bycott, P., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9566 · Cited by 623
Self-citationRixe, O., Bukowski, R. M., Michaelson, M. D., Wilding, G., Hudes, G. R., Bolte, O., Motzer, R. J., Bycott, P., Liau, K. F., Freddo, J., et al. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70285-1 · Cited by 435
Self-citationPhase I Trial of Pazopanib in Patients with Advanced Cancer
Hurwitz, H. I., Dowlati, A., Saini, S., Savage, S., Suttle, A. B., Gibson, D. M., Hodge, J. P., Merkle, E. M., & Pandite, L. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2740 · Cited by 418
FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)
KATOH, M. (2016) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2016.2620 · Cited by 405
An overview of small-molecule inhibitors of VEGFR signaling
Ivy, S. P., Wick, J. Y., & Kaufman, B. M. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.130 · Cited by 350
Eskens, F. A. L. M., & Verweij, J. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.09.015 · Cited by 342
Biology of Platelet-Derived Growth Factor and Its Involvement in Disease
Alvarez, R. H., Kantarjian, H. M., & Cortes, J. E. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.9.1241 · Cited by 334
Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma
Rini, B. I., Wilding, G., Hudes, G., Stadler, W. M., Kim, S., Tarazi, J., Rosbrook, B., Trask, P. C., Wood, L., & Dutcher, J. P. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.7034 · Cited by 325
Self-citationAdenoid cystic carcinoma: A review of recent advances, molecular targets, and clinical trials
Dillon, P. M., Chakraborty, S., Moskaluk, C. A., Joshi, P. J., & Thomas, C. Y. (2016) · Head & Neck · doi:10.1002/hed.23925 · Cited by 307
Heymach, J. V., Johnson, B. E., Prager, D., Csada, E., Roubec, J., Pešek, M., Špásová, I., Belani, C. P., Bodrogi, I., Gadgeel, S., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.5122 · Cited by 293
Self-citationMorabito, A., De Maio, E., Di Maio, M., Normanno, N., & Perrone, F. (2006) · The Oncologist · doi:10.1634/theoncologist.11-7-753 · Cited by 274
Agulnik, M., Cohen, E. W. E., Cohen, R. B., Chen, E. X., Vokes, E. E., Hotte, S. J., Winquist, E., Laurie, S., Hayes, D. N., Dancey, J. E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.8612 · Cited by 263
Liu, G., Rugo, H. S., Wilding, G., McShane, T. M., Evelhoch, J. L., Ng, C., Jackson, E., Kelcz, F., Yeh, B. M., Lee, F. T., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.143 · Cited by 260
Self-citationAnticancer strategies involving the vasculature
Heath, V. L., & Bicknell, R. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.52 · Cited by 255
New therapies for dedifferentiated papillary thyroid cancer
Fallahi, P., Mazzi, V., Vita, R., Ferrari, S., Materazzi, G., Galleri, D., Benvenga, S., Miccoli, P., & Antonelli, A. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16036153 · Cited by 58
“The maximum tolerated dose of axitinib assessed in the first phase I study was 5 mg twice daily [99].”
Background
Metadata
- Authors
- Rugo, H. S., Herbst, R. S., Liu, G., Park, J. W., Kies, M. S., Steinfeldt, H. M., Pithavala, Y. K., Reich, S. D., Freddo, J. L., & Wilding, G.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-08-20
- Volume
- 23
- Issue
- 24
- Pages
- 5474-5483
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2096514095
- Cited by
- 486
- References
- 39
- FWCI
- 11.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.